NIBAN2

Summary

NIBAN2 (niban apoptosis regulator 2, HGNC:25282) is a protein-coding gene on chromosome 9q34.11, encoding Protein Niban 2 (Q96TA1). May play a role in apoptosis suppression.

Enables transcription coactivator activity. Involved in several processes, including gonadotropin secretion; negative regulation of apoptotic process; and regulation of nucleobase-containing compound metabolic process. Located in several cellular components, including adherens junction; cytosol; and nucleoplasm.

Source: NCBI Gene 64855 — RefSeq curated summary.

At a glance

• GWAS associations: 8
• Clinical variants (ClinVar): 172 total — 1 pathogenic
• Druggable target: yes
• MANE Select transcript: NM_022833

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:25282
Approved symbol	NIBAN2
Name	niban apoptosis regulator 2
Location	9q34.11
Locus type	gene with protein product
Status	Approved
Aliases	DKFZP434H0820, FLJ13518, FLJ22151, FLJ22298, bA356B19.6, MINERVA
Ensembl gene	ENSG00000136830
Ensembl biotype	protein_coding
OMIM	614045
Entrez	64855

Gene structure

Transcript identifiers

Ensembl transcripts: 12 — 7 protein_coding, 5 protein_coding_CDS_not_defined

ENST00000373312, ENST00000373314, ENST00000465154, ENST00000468379, ENST00000476091, ENST00000478917, ENST00000484348, ENST00000901130, ENST00000901131, ENST00000901132, ENST00000901133, ENST00000950663

RefSeq mRNA: 2 — MANE Select: NM_022833 NM_001035534, NM_022833

CCDS: CCDS35144, CCDS35145

Canonical transcript exons

ENST00000373312 — 14 exons

Exon	Start	End
ENSE00000806827	127508422	127508538
ENSE00000806828	127508976	127509131
ENSE00000806829	127510146	127510333
ENSE00000806830	127516857	127517019
ENSE00000806831	127517112	127517216
ENSE00000806833	127523679	127523846
ENSE00001151599	127517826	127517941
ENSE00001460181	127568820	127569073
ENSE00001899743	127505343	127507431
ENSE00003495797	127525058	127525163
ENSE00003503540	127507867	127507978
ENSE00003515898	127508093	127508200
ENSE00003626813	127531648	127531778
ENSE00003650563	127527194	127527322

Expression profiles

Bgee: expression breadth ubiquitous, 255 present calls, max score 99.68.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 41.9515 / max 354.9946, expressed in 1729 samples.

FANTOM5 promoters (8 alternative TSS)

Promoter ID	TPM avg	Samples expressed
102547	35.1313	1703
102550	4.9091	1211
102548	0.5996	393
102546	0.5093	306
102545	0.4308	265
102538	0.1871	77
102552	0.1018	36
102551	0.0825	18

Top tissues by expression

255 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
pancreatic ductal cell	CL:0002079	99.68	gold quality
lower esophagus mucosa	UBERON:0035834	99.56	gold quality
esophagus mucosa	UBERON:0002469	99.28	gold quality
esophagus squamous epithelium	UBERON:0006920	98.74	gold quality
pharyngeal mucosa	UBERON:0000355	98.61	gold quality
stromal cell of endometrium	CL:0002255	98.43	gold quality
oral cavity	UBERON:0000167	97.95	gold quality
upper lobe of left lung	UBERON:0008952	97.90	gold quality
tibial nerve	UBERON:0001323	97.72	gold quality
body of pancreas	UBERON:0001150	97.68	gold quality
right lobe of thyroid gland	UBERON:0001119	97.67	gold quality
upper lobe of lung	UBERON:0008948	97.64	gold quality
mucosa of transverse colon	UBERON:0004991	97.62	gold quality
left lobe of thyroid gland	UBERON:0001120	97.61	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	97.53	gold quality
mouth mucosa	UBERON:0003729	97.48	gold quality
minor salivary gland	UBERON:0001830	97.45	gold quality
skin of leg	UBERON:0001511	97.38	gold quality
left adrenal gland cortex	UBERON:0035825	97.32	gold quality
decidua	UBERON:0002450	97.31	gold quality
left adrenal gland	UBERON:0001234	97.30	gold quality
right adrenal gland	UBERON:0001233	97.09	gold quality
skin of abdomen	UBERON:0001416	97.02	gold quality
right adrenal gland cortex	UBERON:0035827	96.98	gold quality
nasal cavity epithelium	UBERON:0005384	96.96	gold quality
gingiva	UBERON:0001828	96.91	gold quality
esophagus	UBERON:0001043	96.90	gold quality
adrenal cortex	UBERON:0001235	96.86	gold quality
right lung	UBERON:0002167	96.82	gold quality
placenta	UBERON:0001987	96.80	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	16.36

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

61 targeting NIBAN2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6127	100.00	66.76	2188
HSA-MIR-4510	100.00	66.60	2050
HSA-MIR-6129	100.00	66.46	2080
HSA-MIR-6130	100.00	66.69	2012
HSA-MIR-6133	100.00	66.48	2064
HSA-MIR-4666A-3P	99.96	71.71	3434
HSA-MIR-6825-5P	99.96	69.81	3431
HSA-MIR-124-3P	99.89	73.74	3043
HSA-MIR-506-3P	99.89	73.55	3057
HSA-MIR-4728-5P	99.85	69.39	4718
HSA-MIR-4739	99.84	65.25	1832
HSA-MIR-1321	99.84	65.30	1811
HSA-MIR-4756-5P	99.84	64.98	1809
HSA-MIR-6785-5P	99.82	68.68	4428
HSA-MIR-8080	99.82	67.52	1342
HSA-MIR-6842-5P	99.80	67.54	1587
HSA-MIR-7110-5P	99.80	67.84	1712
HSA-MIR-4319	99.76	69.83	2586
HSA-MIR-149-3P	99.72	68.22	3963
HSA-MIR-6883-5P	99.69	68.05	3785
HSA-MIR-6887-3P	99.66	67.83	1778
HSA-MIR-1249-5P	99.61	66.55	2049
HSA-MIR-6797-5P	99.61	66.55	2084
HSA-MIR-6132	99.60	65.83	1554
HSA-MIR-3609	99.52	69.89	2587
HSA-MIR-548AH-5P	99.52	69.73	2626
HSA-MIR-4441	99.49	66.56	3216
HSA-MIR-125A-5P	99.36	70.59	1640
HSA-MIR-125B-5P	99.36	70.36	1662
HSA-MIR-7515	99.31	68.22	1795

Literature-anchored findings (GeneRIF, showing 5)

• Phosphorylation of FAM129B has a role in controlling melanoma cell invasion. (PMID:19362540)
• The rapid induction of apoptosis in FAM129B knockdown cells was reversed by co-transfection with recombinant FAM129B, indicating that its effect on apoptosis was specific. (PMID:21148485)
• activated EGFR phosphorylates the Y593 residue of the protein known as family with sequence similarity 129, member B (FAM129B), which is overexpressed in many types of human cancer. (PMID:26721396)
• We have demonstrated that FAM129B in cancer promotes Nrf2 activity by reducing its ubiquitination through competition with Nrf2 for Keap1 binding via its DLG and ETGE motifs. In addition, FAM129B reduces chemosensitivity by augmenting Nrf2 antioxidative signaling and confers poor prognosis in breast and lung cancer (PMID:31262713)
• Structural Insight on Functional Regulation of Human MINERVA Protein. (PMID:33142954)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	niban2b	ENSDARG00000008026
danio_rerio	niban2a	ENSDARG00000062970
mus_musculus	Niban2	ENSMUSG00000026796
rattus_norvegicus	Niban2	ENSRNOG00000015845

Paralogs (2): NIBAN1 (ENSG00000135842), NIBAN3 (ENSG00000167483)

Protein

Protein identifiers

Protein Niban 2 — Q96TA1 (reviewed: Q96TA1)

Alternative names: Meg-3, Melanoma invasion by ERK, Niban-like protein 1, Protein FAM129B

All UniProt accessions (1): Q96TA1

UniProt curated annotations — full annotation on UniProt →

Function. May play a role in apoptosis suppression. May promote melanoma cell invasion in vitro.

Subcellular location. Cytoplasm. Cytosol. Cell junction. Adherens junction. Membrane.

Post-translational modifications. Phosphorylated at Ser-641, Ser-646, Ser-692 and Ser-696 by the BRAF/MKK/ERK signaling cascade. In melanoma cells, the C-terminal phosphorylation may prevent targeting to the plasma membrane. As apoptosis proceeds, degraded via an proteasome-independent pathway, probably by caspases.

Similarity. Belongs to the Niban family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q96TA1-1	1	yes
Q96TA1-2	2

RefSeq proteins (2): NP_001030611, NP_073744* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001849	PH_domain	Domain
IPR011993	PH-like_dom_sf	Homologous_superfamily
IPR026088	Niban-like	Family
IPR059060	Niban_1/2/3_dom	Domain

Pfam: PF26086, PF26089

UniProt features (71 total): helix 20, modified residue 14, mutagenesis site 12, strand 9, turn 6, sequence conflict 2, compositionally biased region 2, initiator methionine 1, chain 1, domain 1, lipid moiety-binding region 1, splice variant 1, region of interest 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
7CTP	X-RAY DIFFRACTION	1.8

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q96TA1-F1	81.06	0.64

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (15): 606, 609, 624, 638, 641, 646, 665, 681, 692, 696, 2, 568, 574, 601, 603

Mutagenesis-validated functional residues (12):

Position	Phenotype
641	loss of melanoma cell invasion; when associated with a-646; a-665; a-681; a-679 and a-683.
641	promotes melanoma cell invasion; when associated with d/e-633; d/e-652; d/e-668; d/e-679 and d/e-683.
646	loss of melanoma cell invasion; when associated with a-641; a-665; a-681; a-679 and a-683.
646	promotes melanoma cell invasion; when associated with d/e-628; d/e-652; d/e-668; d/e-679 and d/e-683.
665	loss of melanoma cell invasion; when associated with a-641; a-646; a-681; a-679 and a-683.
665	promotes melanoma cell invasion; when associated with d/e-628; d/e-633; d/e-668; d/e-679 and d/e-683.
681	loss of melanoma cell invasion; when associated with a-641; a-646; a-665; a-679 and a-683.
681	promotes melanoma cell invasion; when associated with d/e-628; d/e-633; d/e-652; d/e-679 and d/e-683.
692	loss of melanoma cell invasion; when associated with a-641; a-646; a-665; a-668 and a-683.
692	promotes melanoma cell invasion; when associated with d/e-628; d/e-633; d/e-652; d/e-668 and d/e-683.
696	loss of melanoma cell invasion; when associated with a-641; a-646; a-665; a-668 and a-679.
696	promotes melanoma cell invasion; when associated with d/e-628; d/e-633; d/e-652; d/e-668 and d/e-679.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 194 (showing top): GOBP_REGULATION_OF_HORMONE_LEVELS, GOBP_HORMONE_TRANSPORT, GOBP_CELL_CELL_SIGNALING, GOBP_POSITIVE_REGULATION_OF_BINDING, GTGCCTT_MIR506, MODULE_205, GOBP_POSITIVE_REGULATION_OF_MOLECULAR_FUNCTION, GOBP_NEGATIVE_REGULATION_OF_DNA_BIOSYNTHETIC_PROCESS, GOBP_SECRETION, LIAO_METASTASIS, GOBP_SIGNAL_RELEASE, GOBP_DNA_BIOSYNTHETIC_PROCESS, GOBP_POSITIVE_REGULATION_OF_TRANSCRIPTION_REGULATORY_REGION_DNA_BINDING, GOBP_REGULATION_OF_DNA_BIOSYNTHETIC_PROCESS, ACTTTAT_MIR1425P

GO Biological Process (7): negative regulation of cell population proliferation (GO:0008285), gonadotropin secretion (GO:0032274), negative regulation of apoptotic process (GO:0043066), negative regulation of DNA-templated transcription (GO:0045892), positive regulation of DNA-templated transcription (GO:0045893), negative regulation of DNA biosynthetic process (GO:2000279), positive regulation of transcription regulatory region DNA binding (GO:2000679)

GO Molecular Function (3): transcription coactivator activity (GO:0003713), cadherin binding (GO:0045296), protein binding (GO:0005515)

GO Cellular Component (9): nucleus (GO:0005634), nucleoplasm (GO:0005654), cytoplasm (GO:0005737), cytosol (GO:0005829), plasma membrane (GO:0005886), adherens junction (GO:0005912), extracellular exosome (GO:0070062), membrane (GO:0016020), anchoring junction (GO:0070161)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	4
DNA-templated transcription	2
regulation of DNA-templated transcription	2
cell population proliferation	1
regulation of cell population proliferation	1
negative regulation of cellular process	1
hormone secretion	1
apoptotic process	1
regulation of apoptotic process	1
negative regulation of programmed cell death	1
negative regulation of RNA biosynthetic process	1
positive regulation of RNA biosynthetic process	1
negative regulation of macromolecule biosynthetic process	1
negative regulation of DNA metabolic process	1
DNA biosynthetic process	1
regulation of DNA biosynthetic process	1
transcription cis-regulatory region binding	1
positive regulation of DNA binding	1
regulation of transcription regulatory region DNA binding	1
transcription coregulator activity	1
positive regulation of DNA-templated transcription	1
cell adhesion molecule binding	1
binding	1
intracellular membrane-bounded organelle	1
nuclear lumen	1
intracellular anatomical structure	1
cytoplasm	1
membrane	1
cell periphery	1
cell-cell junction	1
extracellular vesicle	1
cell junction	1

Protein interactions and networks

STRING

2055 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
NIBAN2	TMEM120B	A0PK00	475
NIBAN2	RHOF	Q9HBH0	410
NIBAN2	C5orf52	A6NGY3	397
NIBAN2	DPP3	Q9NY33	372
NIBAN2	KEAP1	Q14145	369
NIBAN2	OR8G1	Q15617	365
NIBAN2	SUZ12	Q15022	353
NIBAN2	HS1BP3	Q53T59	352
NIBAN2	GABARAPL2	P60520	348
NIBAN2	CHD6	Q8TD26	337
NIBAN2	OR51F1	A6NGY5	321
NIBAN2	GAPDH	P00354	314
NIBAN2	TMEM120A	Q9BXJ8	313
NIBAN2	DENND10	Q8TCE6	310
NIBAN2	SAMD10	Q9BYL1	304

IntAct

100 interactions, top by confidence:

A	B	Type	Score
KEAP1	NFE2L2	psi-mi:“MI:0914”(association)	0.980
AKR7A3	AKR7A2	psi-mi:“MI:0914”(association)	0.890
NIBAN2	KEAP1	psi-mi:“MI:0915”(physical association)	0.720
NIBAN2	KEAP1	psi-mi:“MI:0403”(colocalization)	0.720
NIBAN2	KEAP1	psi-mi:“MI:2364”(proximity)	0.720
CFTR	ESYT2	psi-mi:“MI:0914”(association)	0.710
CFTR	ESYT2	psi-mi:“MI:2364”(proximity)	0.710
KCNJ2	KCNJ18	psi-mi:“MI:2364”(proximity)	0.660
IGF1R	PIK3R2	psi-mi:“MI:2364”(proximity)	0.590
INSR	PIK3R2	psi-mi:“MI:2364”(proximity)	0.570
MSRB2	BLTP3B	psi-mi:“MI:0914”(association)	0.530
	NIBAN2	psi-mi:“MI:0407”(direct interaction)	0.520
CFTR	PLEKHG3	psi-mi:“MI:0914”(association)	0.480
NIBAN2	Niban2	psi-mi:“MI:0915”(physical association)	0.400
ZNF512B	NIBAN2	psi-mi:“MI:0915”(physical association)	0.370
LRRK2		psi-mi:“MI:0914”(association)	0.350

BioGRID (178): FAM129B (Affinity Capture-MS), FAM129B (Proximity Label-MS), FAM129B (Affinity Capture-MS), FAM129B (Affinity Capture-MS), FAM129B (Affinity Capture-Western), FAM129B (Reconstituted Complex), FAM129B (Biochemical Activity), FAM129B (Affinity Capture-Western), HRAS (Affinity Capture-Western), KRAS (Affinity Capture-Western), FAM129B (Proximity Label-MS), FAM129B (Proximity Label-MS), FAM129B (Proximity Label-MS), FAM129B (Affinity Capture-MS), FAM129B (Affinity Capture-MS)

ESM2 similar proteins: A2AQ25, A6H7A8, B0R1D5, B4F7E8, E9PSK7, F1R7R1, O00472, O14795, P12755, P17863, P49140, Q50H33, Q5DTY9, Q5FVG6, Q5R595, Q5R6Y9, Q5RHQ8, Q5ZJK1, Q60698, Q62739, Q62769, Q68DU8, Q6DC03, Q6PCM2, Q6ZWB6, Q7SYD9, Q80U62, Q812A5, Q8BYR5, Q8CID0, Q8N228, Q8N5Y2, Q8R1F1, Q8TEK3, Q8VDD9, Q8VI24, Q91Y53, Q92622, Q96QF0, Q96TA1

Diamond homologs: B4F7E8, Q3UW53, Q8R1F1, Q96TA1, Q9BZQ8, Q9ESN0

SIGNOR signaling

3 interactions.

A	Effect	B	Mechanism
EGFR	“up-regulates activity”	NIBAN2	phosphorylation
NIBAN2	“up-regulates activity”	HRAS	binding
BRAF	“down-regulates activity”	NIBAN2	phosphorylation

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 98 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Constitutive Signaling by Aberrant PI3K in Cancer	6	11.7×	3e-03
PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling	7	10.4×	2e-03
PIP3 activates AKT signaling	7	7.2×	8e-03

GO biological processes:

GO term	Partners	Fold	FDR
protein autophosphorylation	7	11.7×	2e-03
positive regulation of cell migration	9	6.4×	5e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

172 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	145
Likely benign	7
Benign	0

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
1527561	GRCh37/hg19 9q34.11(chr9:130306022-130522616)	Pathogenic

SpliceAI

2884 predictions. Top by Δscore:

Variant	Effect	Δscore
9:127507427:CACAG:C	acceptor_gain	1.0000
9:127507428:ACAG:A	acceptor_gain	1.0000
9:127507429:CAG:C	acceptor_gain	1.0000
9:127507429:CAGC:C	acceptor_gain	1.0000
9:127507430:AG:A	acceptor_gain	1.0000
9:127507430:AGC:A	acceptor_loss	1.0000
9:127507431:GCTA:G	acceptor_loss	1.0000
9:127507432:C:CC	acceptor_gain	1.0000
9:127507441:C:CT	acceptor_gain	1.0000
9:127507441:C:T	acceptor_gain	1.0000
9:127507862:CCCA:C	donor_loss	1.0000
9:127507863:CCAC:C	donor_loss	1.0000
9:127507864:CACC:C	donor_loss	1.0000
9:127507865:A:AC	donor_gain	1.0000
9:127507865:AC:A	donor_gain	1.0000
9:127507866:C:CA	donor_gain	1.0000
9:127507866:C:CC	donor_gain	1.0000
9:127507866:CCCTG:C	donor_gain	1.0000
9:127507878:T:TA	donor_gain	1.0000
9:127507882:T:TA	donor_gain	1.0000
9:127507905:T:TA	donor_gain	1.0000
9:127507974:AGCTC:A	acceptor_gain	1.0000
9:127507976:CTC:C	acceptor_gain	1.0000
9:127507977:TC:T	acceptor_gain	1.0000
9:127507978:CC:C	acceptor_gain	1.0000
9:127507979:C:CC	acceptor_gain	1.0000
9:127507983:CCGGG:C	acceptor_gain	1.0000
9:127507984:C:T	acceptor_gain	1.0000
9:127507984:CGGG:C	acceptor_gain	1.0000
9:127507985:G:T	acceptor_gain	1.0000

AlphaMissense

4888 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
9:127507949:G:C	F524L	0.999
9:127507949:G:T	F524L	0.999
9:127507951:A:G	F524L	0.999
9:127508148:A:G	L496P	0.999
9:127508152:C:G	A495P	0.999
9:127508183:G:C	S484R	0.999
9:127508183:G:T	S484R	0.999
9:127508185:T:G	S484R	0.999
9:127510238:C:G	G357R	0.999
9:127510258:A:G	L350P	0.999
9:127510267:A:G	L347P	0.999
9:127510291:A:T	V339D	0.999
9:127508112:A:G	L508P	0.998
9:127508121:A:G	L505P	0.998
9:127508124:A:G	L504P	0.998
9:127508172:C:G	R488P	0.998
9:127508187:T:A	D483V	0.998
9:127509030:A:C	F421L	0.998
9:127509030:A:T	F421L	0.998
9:127509032:A:G	F421L	0.998
9:127510242:G:C	S355R	0.998
9:127510242:G:T	S355R	0.998
9:127510244:T:G	S355R	0.998
9:127516874:A:G	L319P	0.998
9:127517881:C:G	R217P	0.998
9:127517897:C:G	A212P	0.998
9:127527256:A:G	W85R	0.998
9:127527256:A:T	W85R	0.998
9:127507887:A:T	V545D	0.997
9:127507899:A:T	V541E	0.997

dbSNP variants (sampled 300 via entrez): RS1000042576 (9:127504878 G>A,C), RS1000045118 (9:127540887 C>T), RS1000096891 (9:127541086 G>A,C,T), RS1000163333 (9:127570211 T>C), RS1000178709 (9:127544011 G>A), RS1000189777 (9:127562017 G>A), RS1000299488 (9:127519412 A>C), RS1000304907 (9:127530048 G>A), RS1000318648 (9:127535520 G>A), RS1000326757 (9:127517333 A>G), RS1000473419 (9:127561682 G>A), RS1000519996 (9:127505202 G>A,T), RS1000523940 (9:127563094 C>T), RS1000533671 (9:127526474 C>A,T), RS1000569084 (9:127506216 C>T)

Disease associations

OMIM: gene MIM:614045 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

8 associations (top):

Study	Trait	p-value
GCST006288_304	Heel bone mineral density	2.000000e-10
GCST006288_622	Heel bone mineral density	1.000000e-10
GCST006624_65	Systolic blood pressure	3.000000e-12
GCST006979_553	Heel bone mineral density	9.000000e-26
GCST011066_1	Motor fluctuations in levodopa treated Parkinson’s disease	7.000000e-06
GCST90002390_398	Mean corpuscular hemoglobin	8.000000e-10
GCST90002400_388	Plateletcrit	1.000000e-09
GCST90002402_72	Platelet count	4.000000e-11

EFO canonical traits (7, from GWAS)

EFO ID	Trait name
EFO:0009270	heel bone mineral density
EFO:0006335	systolic blood pressure
EFO:0010747	response to levodopa
EFO:0010749	motor function measurement
EFO:0004527	mean corpuscular hemoglobin
EFO:0007985	platelet crit
EFO:0004309	platelet count

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL6067097 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

47 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, increases expression, decreases expression	5
bisphenol A	decreases expression, decreases methylation, increases expression	3
sodium arsenite	increases expression	2
Phenylmercuric Acetate	affects cotreatment, increases expression	2
Tobacco Smoke Pollution	affects expression, decreases expression	2
Cyclosporine	decreases expression, increases expression	2
FR900359	affects phosphorylation	1
bisphenol F	increases expression	1
propylparaben	increases expression	1
lead acetate	increases expression	1
pyrogallol 1,3-dimethyl ether	affects cotreatment, decreases expression, affects localization	1
trichostatin A	increases expression	1
methylparaben	increases expression	1
cobaltous chloride	increases expression	1
perfluorooctanoic acid	decreases expression	1
cupric chloride	increases expression	1
phenanthrene	decreases expression	1
perfluorodecanoic acid	decreases expression	1
beta-methylcholine	affects expression	1
perfluoro-n-nonanoic acid	decreases expression	1
2-palmitoylglycerol	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
erucylphospho-N,N,N-trimethylpropylammonium	increases expression	1
bisphenol B	increases expression	1
abrine	decreases expression	1
dorsomorphin	increases expression, affects cotreatment	1
jinfukang	affects cotreatment, increases expression	1
bisphenol AF	increases expression	1
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid	increases expression	1
Sunitinib	decreases expression	1

ChEMBL screening assays

1 unique, capped per target: 1 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5651402	Binding	Binding affinity to human FAM129B incubated for 45 mins by Kinobead based pull down assay	NVP-BHG712: Effects of Regioisomers on the Affinity and Selectivity toward the EPHrin Family. — ChemMedChem

Cellosaurus cell lines

1 cell lines: 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B3CD	Abcam HEK293T NIBAN2 KO	Transformed cell line	Female

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.